Author pages are created from data sourced from our academic publisher partnerships and public sources.
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
MYC contributes to the pathogenesis of a majority of human cancers, yet strategies to modulate the function of the c-Myc oncoprotein do not exist. Toward this objective, we have targeted MYC… Expand
Biological properties of extracellular vesicles and their physiological functions
- M. Yáñez-Mó, P. Siljander, +57 authors O. De Wever
- Biology, Medicine
- Journal of extracellular vesicles
- 1 January 2015
In the past decade, extracellular vesicles (EVs) have been recognized as potent vehicles of intercellular communication, both in prokaryotes and eukaryotes. This is due to their capacity to transfer… Expand
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.
Detailed genomic studies have shown that cytogenetic abnormalities contribute to multiple myeloma (MM) pathogenesis and disease progression. Nevertheless, little is known about the characteristics of… Expand
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.
- A. Roccaro, A. Sacco, +10 authors I. Ghobrial
- The Journal of clinical investigation
- 1 April 2013
BM mesenchymal stromal cells (BM-MSCs) support multiple myeloma (MM) cell growth, but little is known about the putative mechanisms by which the BM microenvironment plays an oncogenic role in this… Expand
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
The mechanisms by which multiple myeloma (MM) cells migrate and home to the bone marrow are not well understood. In this study, we sought to determine the effect of the chemokine SDF-1 (CXCL12) and… Expand
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
This phase 1/2 study is the first prospective evaluation of lenalidomide-bortezomib-dexamethasone in front-line myeloma. Patients (N = 66) received 3-week cycles (n = 8) of bortezomib 1.0 or 1.3… Expand
Bone Marrow Microenvironment in Multiple Myeloma Progression
- S. Manier, A. Sacco, X. Leleu, I. Ghobrial, A. Roccaro
- Medicine, Biology
- Journal of biomedicine & biotechnology
- 3 October 2012
Substantial advances have been made in understanding the biology of multiple myeloma (MM) through the study of the bone marrow (BM) microenvironment. Indeed, the BM niche appears to play an important… Expand
Genomic complexity of multiple myeloma and its clinical implications
- S. Manier, Karma Z. Salem, J. Park, D. Landau, G. Getz, I. Ghobrial
- Biology, Medicine
- Nature Reviews Clinical Oncology
- 1 February 2017
Multiple myeloma (MM) is a genetically complex disease that evolves from pre-malignant stages, such as monoclonal gammaopathy of undetermined significance and smouldering multiple myeloma, and… Expand
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.
The spread of multiple myeloma (MM) involves (re)circulation into the peripheral blood and (re)entrance or homing of MM cells into new sites of the BM. Hypoxia in solid tumors was shown to promote… Expand
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkin's lymphoma (NHL). Everolimus is an oral agent that targets… Expand